Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy

Anti-PD-1 and anti-PD-L1 immunotherapy has provided a new therapeutic opportunity for treatment of advanced-stage non-small cell lung cancer (NSCLC). However, overall objective response rates are approximately 15%–25% in all NSCLC patients who receive anti-PD therapy. Therefore, strategies to overco...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Yan, Xiang, Wang, Li, Zhang, Ran, Pu, Xingxiang, Wu, Shuhong, Yu, Lili, Meraz, Ismail M., Zhang, Xiaoshan, Wang, Jacqueline F., Gibbons, Don L., Mehran, Reza J., Swisher, Stephen G., Roth, Jack A., Fang, Bingliang
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739569/
https://ncbi.nlm.nih.gov/pubmed/29296537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1376156
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados